| 臺大學術典藏 |
2022-08-10T02:37:42Z |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
CHIH-HSIN YANG; Reckamp K.L.; Kim Y.-C.; Novello S.; Smit E.F.; Lee J.-S.; Su W.-C.; Akerley W.L.; Blakely C.M.; Groen H.J.M.; Bazhenova L.; Carcereny Costa E.; Chiari R.; Hsia T.-C.; Golsorkhi T.; Despain D.; Shih D.; Popat S.; Wakelee H. |
| 臺大學術典藏 |
2022-08-10T02:37:39Z |
Brigatinib vs alectinib in crizotinib-resistant advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALTA-3)
|
Popat S.; Liu G.; Lu S.; Song G.; Ma X.; CHIH-HSIN YANG |
| 臺大學術典藏 |
2022-08-10T02:37:38Z |
Brigatinib Versus Crizotinib in ALK Inhibitor�VNaive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
|
Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garcia Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.I.; Gettinger S.N.; Tiseo M.; Lin H.M.; Liu Y.; Vranceanu F.; Niu H.; Zhang P.; Popat S. |
| 臺大學術典藏 |
2022-06-27T02:49:08Z |
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
|
Popat S.; Hsia T.-C.; Hung J.-Y.; Jung H.A.; JIN-YUAN SHIH; Park C.K.; Lee S.H.; Okamoto T.; Ahn H.K.; Lee Y.C.; Sato Y.; Lee S.S.; Mascaux C.; Daoud H.; M?rten A.; Miura S. |
| 臺大學術典藏 |
2021-04-23T05:56:29Z |
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
|
Chih-Hsin Yang;Schuler M.;Popat S.;Miura S.;Heeke S.;Park K.;M?Rten A.;Kim E.S.; CHIH-HSIN YANG; Schuler M.; Popat S.; Miura S.; Heeke S.; Park K.; M?rten A.; Kim E.S. |
| 臺大學術典藏 |
2021-04-23T05:56:27Z |
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor�VNaive ALK-Positive Non�VSmall Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
|
Camidge D.R.;Kim H.R.;Ahn M.-J.;Chih-Hsin Yang;Han J.-Y.;Hochmair M.J.;Lee K.H.;Delmonte A.;Garc?A Campelo M.R.;Kim D.-W.;Griesinger F.;Felip E.;Califano R.;Spira A.;Gettinger S.N.;Tiseo M.;Lin H.M.;Gupta N.;Hanley M.J.;Ni Q.;Zhang P.;Popat S.; Camidge D.R.; Kim H.R.; Ahn M.-J.; CHIH-HSIN YANG; Han J.-Y.; Hochmair M.J.; Lee K.H.; Delmonte A.; Garc?a Campelo M.R.; Kim D.-W.; Griesinger F.; Felip E.; Califano R.; Spira A.; Gettinger S.N.; Tiseo M.; Lin H.M.; Gupta N.; Hanley M.J.; Ni Q.; Zhang P.; Popat S. |
| 國立成功大學 |
2021 |
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
|
Yang, J.C.-H.;Reckamp, K.L.;Kim, Y.-C.;Novello, S.;Smit, E.F.;Lee, J.-S.;Su, W.-C.;Akerley, W.L.;Blakely, C.M.;Groen, H.J.M.;Bazhenova, L.;Carcereny, Costa E.;Chiari, R.;Hsia, T.-C.;Golsorkhi, T.;Despain, Despain D.;Shih, D.;Popat, S.;Wakelee, H. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis
|
Popat S;Mok T;Chih-Hsin Yang;Wu Y.-L;Lungershausen J;Stammberger U;Griebsch I;Fonseca T;Paz-Ares L.; Popat S; Mok T; CHIH-HSIN YANG; Wu Y.-L; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:58Z |
Afatinib in the treatment of EGFR mutation-positive NSCLC - A network meta-analysis
|
Popat S;Mok T;Chih-Hsin Yang;Wu Y.-L;Lungershausen J;Stammberger U;Griebsch I;Fonseca T;Paz-Ares L.; Popat S; Mok T; CHIH-HSIN YANG; Wu Y.-L; Lungershausen J; Stammberger U; Griebsch I; Fonseca T; Paz-Ares L. |
| 臺大學術典藏 |
2020-05-26T09:26:54Z |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials
|
Sequist L.V.;Zazulina V;Shahidi M;Massey D;Kato T;Lee K.H;Su W.-C;Boyer M;Mok T;Orlov S;Bennouna J;Hirsh V;Gorbunova V;Tsai C.-M;Lee K.Y;Geater S.L;Huang Y;Lu S;Feng J;O'Byrne K;Hu C.-P;Zhou C;Yamamoto N;Popat S;Sebastian M;Schuler M;Wu Y.-L;Chih-Hsin Yang; CHIH-HSIN YANG; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. |
